Rigel Q2 2024 Earnings Report
Key Takeaways
Rigel Pharmaceuticals reported total revenues of $36.8 million for the second quarter of 2024, driven by record sales of TAVALISSE and REZLIDHIA, as well as the addition of GAVRETO to their commercial portfolio. The company reported a net loss of $1.0 million, approaching net income break even.
Total revenues were $36.8 million, driven by TAVALISSE, REZLIDHIA, GAVRETO net product sales, and contract revenue from collaborations.
TAVALISSE net product sales grew 24% compared to the same period in 2023.
REZLIDHIA net product sales grew 102% compared to the same period in 2023.
GAVRETO became commercially available from Rigel on June 27, 2024.
Rigel
Rigel
Forward Guidance
The company looks to maintain their financial discipline as they expand their commercial reach and advance their development programs.